DarioHealth Corp.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
DRIO$2.39+16.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Interim Statements of Cash Flows (Unaudited)
U.S. dollars in thousands
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Three months ended | ||||||
| · · March 31, | ||||||
| | 2025 | 2024 | ||||
| Cash flows from operating activities: | | | | | | |
| Net loss | | $(9,227) | | $(7,175) | ||
| Adjustments required to reconcile net loss to net cash used in operating activities: | | | | | ||
| Stock-based compensation | | 2,342 | | 6,858 | ||
| Depreciation and impairment | | 94 | | 110 | ||
| Change in operating lease right of use assets | | 110 | | 149 | ||
| Amortization of acquired intangible assets | | 1,162 | | 1,216 | ||
| Decrease (increase) in trade receivables, net | | 1,597 | | (1,401) | ||
| Increase in other accounts receivable, prepaid expense and long-term assets | | (369) | | (1,866) | ||
| Decrease (increase) in inventories | | 130 | | 146 | ||
| Increase (decrease) in trade payables | | (300) | | 708 | ||
| Decrease in other accounts payable and accrued expenses | | (1,666) | | (2,620) | ||
| Increase (decrease) in deferred revenues | | (278) | | 52 | ||
| Change in operating lease liabilities | | (126) | | (18) | ||
| Change in fair value of warrant liability | | (1,115) | | (9,181) | ||
| Non-cash financial expenses (income) | | 293 | | (83) | ||
| Other | | 680 | | (5) | ||
| | | | | | | |
| Net cash used in operating activities | | (6,673) | | (13,110) | ||
| | | | | | | |
| Cash flows from investing activities: | | | ||||
| Purchase of property and equipment | | (31) | | (56) | ||
| Payments for business acquisitions, net of cash acquired | | | — | | | (8,796) |
| | | | | | | |
| Net cash used in investing activities | | (31) | | (8,852) | ||
| | | | | | | |
| Cash flows from financing activities: | | | | | ||
| Proceeds from issuance of preferred stock, net of issuance costs | | 6,815 | | 20,206 | ||
| | | | | | | |
| Net cash provided by financing activities | | 6,815 | | 20,206 | ||
| | | | | | | |
| Increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents | | 111 | | (1,756) | ||
| Effect of exchange rate differences on cash, cash equivalents and restricted cash and cash equivalents | | | (21) | | | — |
| Cash, cash equivalents and restricted cash and cash equivalents at beginning of period | | 27,764 | | 36,797 | ||
| Cash, cash equivalents and restricted cash and cash equivalents at end of period | | $27,854 | | $35,041 | ||
| Supplemental disclosure of cash flow information: | | | | |||
| Cash paid during the period for interest on long-term loan | | $937 | | $986 | ||
| Non-cash activities: | | | | |||
| Right-of-use assets obtained in exchange for lease liabilities | | $— | | $28 | ||
| Exercise of pre-funded warrants to common stock upon acquisition | | $1,750 | | $— | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.